You are now leaving GSK’s website

You are now leaving a GSK Website. By clicking this link, you will be taken to a website that is not owned or controlled by GSK, and GSK is not responsible for the content provided on that site.

Continue

Go back

NA NA

Want to know more about BLENREP (belantamab mafodotin)?

Get in touch with your local GSK Ireland Team today to learn more.

Adverse event reporting information can be found at the bottom of this page

Summary of product characteristics & Patient information leaflet for Blenrep 70mg/100mg powder for concentrate for solution for infusion

INDICATION

Blenrep is indicated in adults for the treatment of relapsed or refractory multiple myeloma:

  • in combination with bortezomib and dexamethasone in patients who have received at least one prior therapy; and
  • in combination with pomalidomide and dexamethasone in patients who have received at least one prior therapy including lenalidomide.

Reference

  1. BLENREP. Summary of Product Characteristics. GlaxoSmithKline. 2026.

Adverse events should be reported directly to the Health Products Regulatory Authority (HPRA) on their website: www.hpra.ie. Adverse events should also be reported to GlaxoSmithKline on 1800 244 255 or via the online form gsk.public.reportum.com

▼This medicine is subject to additional monitoring. This will allow quick identification of new safety information.

BLENREP is a registered trademark of the GlaxoSmithKline group of companies.

Get more from GSKpro

Get access to exclusive events on the topics that matter to you, free patient resources including patient support materials, demo devices and updates on the latest in HIV/AIDS, respiratory, oncology and vaccines.

Register in 2 Minutes

PM-IE-BLM-WCNT-260002 | July 2026